BTK Inhibitors as Sensitizing Agents in Solid Tumors

Texte du rabat

BTK Inhibitors as Sensitizing Agents in Solid Tumors provides a thorough review of mechanisms of multi-drug resistance in cancers, describing, in detail, the mechanisms, current studies and future directions of the role of BTK inhibitors in overcoming therapy resistance in cancer, including resistance to chemotherapy, targeted therapies and immunotherapy. The book discusses topics such as mechanisms of therapy resistance in cancer cells, BTK inhibitors in paclitaxel, docetaxel, platinum, BRAF and radio resistance. In addition, the book discusses ibrutinib and its role in immunotherapy resistance, novel BTK inhibitors and future perspectives.

This book is a valuable resource for cancer researchers, oncologists, graduate students, and members of the biomedical field who are interested in the potential of BTK inhibitors as sensitizing agent to resistant cancers.

Contenu

1. Overview of BTK pathway
   
   2. Overview of BTK inhibitors and their clinical utility [1st gen, 2nd gen]
   3. Mechanisms of therapy resistance in cancer cells
   4. BTK inhibitors in paclitaxel and docetaxel resistance
   5. BTK inhibitors in Platinum resistance
   6. BTK inhibitors in BRAF resistance
   7. BTK inhibitors in radio-resistance
   8. Ibrutinib beyond BTK inhibition and role in immunotherapy resistance
   9. Novel BTK inhibitors and future perspectives